Eugenics after the Nazis? The Evolution of a Problematic Discipline
By Christos Konstantopoulos,
The Collector
| 04. 27. 2023
What is the first period that comes to mind when one hears the term “eugenics”? For many, the answer is obvious: the Nazi dictatorship in Germany (1933-1945). And for good reason. The Nazis were indeed outspoken proponents of eugenics, carrying out multiple eugenic policies, including the T-4 involuntary euthanization program and compulsory sterilizations. The aim? To uplift and “purify” the “Aryan race” by weeding out “undesirables” from the gene pool and increasing the number of those deemed to be of “sound” genetic material. Nevertheless, the obsession of popular culture with World War II has obscured an uncomfortable truth: the survival of eugenic ideas after the collapse of Nazism. Rather than ending abruptly, modern eugenics was gradually phased out and ingeniously re-invented, allowing it to survive past 1945.
Optimizing Mankind: Eugenics Before the Nazis
In her book Controlling Human Heredity, historian of genetics Diane Paul explains that manipulating human reproduction to optimize a population’s traits is an old idea. Utopian thinkers, such as Plato in the 4th century BCE, and Tommaso Campanella in the 17th century CE, frequently formulated such...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...